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Abstract Naive CD4+ T cells differentiate into two types of
helper T cells showing an interferon-Q-predominant (Th1) or an
interleukin-4-predominant (Th2) cytokine secretion profile after
repeated antigenic stimulation. Their differentiation can be
influenced by slight differences in the interaction between the
T cell receptor (TCR) and its ligand at the time of primary
activation. However, the primary response of freshly isolated
naive CD4+ T cells to altered TCR ligands is still unclear. Here,
we investigated the primary response of splenic naive CD4+ T
cells derived from transgenic mice expressing TCR specific for
residues 323^339 of ovalbumin (OVA323^339) bound to I-Ad
molecules. Naive CD4 T cells secreted either Th1- or Th2-type
cytokines immediately after stimulation with OVA323^339 or its
single amino acid-substituted analogs. Helper activity for anti-
body secretion by co-cultured resting B cells was also found in the
primary response, accompanied by either low-level Th2-type
cytokine secretion or no apparent cytokine secretion. Our results
clearly indicate that dichotomy of the Th1/Th2 cytokine
secretion profile can be elicited upon primary activation of naive
CD4+ T cells. We also demonstrate that the helper activity of
naive CD4+ T cells for antibody production does not correspond
to the amounts of the relevant cytokines secreted.
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1. Introduction
CD4 T cells recognize antigenic peptides bound to major
histocompatibility complex (MHC) class II molecules through
their T cell receptor (TCR). Naive CD4 T cells activated
upon stimulation with speci¢c antigens start to di¡erentiate
into two distinct types of e¡ector cells each showing a partic-
ular cytokine secretion pro¢le and particular immune regula-
tory functions [1]. Th1 cells produce interleukin (IL)-2, inter-
feron (IFN)-Q, and lymphotoxin and contribute to cell-
mediated immune responses, whereas Th2 cells produce IL-
4, IL-5, and IL-10, and are e⁄cient in providing help for
antibody production by B cells.
A large number of studies have revealed that T cell re-
sponses are modi¢ed upon stimulation of these cells with cer-
tain amino acid-substituted analogs of an antigenic peptide, as
these substitutions result in slight changes in the interaction
between TCR and the peptide/MHC complexes. These pep-
tides are called altered peptide ligands [2]. Recent studies
have shown that the altered TCR/peptide/MHC interaction
strongly a¡ects the di¡erentiation of naive CD4 T cells
into Th1 or Th2 cells. Bottomly et al. [3] have demonstrated
that naive CD4 T cells cultured in the presence of a wild-
type peptide or one of its single amino acid-substituted ana-
logs during primary culture secreted Th1- or Th2-type cyto-
kines, respectively, after secondary stimulation with the wild-
type peptide. It has also been demonstrated that varying the
dose of antigen used in primary stimulation a¡ects the Th1/
Th2 di¡erentiation of naive CD4 T cells [4,5]. These results
suggest that di¡erences in the primary response of naive
CD4 T cells in£uence their di¡erentiation into Th1/Th2 cells.
However, the previous studies exclusively focused on the sec-
ondary cytokine response of naive CD4 T cells, and thus it is
unclear whether freshly isolated naive CD4 T cells secrete
Th1- or Th2-type cytokines after recognizing speci¢c antigens
for the ¢rst time in vitro. It is also unknown whether naive
CD4 T cells exhibit other activation characteristics besides
cytokine secretion.
In this study, we used naive CD4 T cells from OVA23-3
transgenic mice [6] which express TCR K and L chains speci¢c
for a peptide corresponding to residues 323^339 of ovalbumin
(OVA323^339) in complex with an I-Ad molecule, a murine
MHC class II molecule. We investigated the primary activa-
tion of naive CD4 T cells in response to a panel of 40 single
amino acid-substituted analogs of OVA323^339. These analog
peptides each carried a substituted amino acid residue at a
putative TCR contact site. Here, we demonstrate that naive
CD4 T cells can exhibit a Th1- or Th2-type cytokine re-
sponse upon primary activation, depending on the amino
acid sequence of the antigenic peptide. We also found that
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naive CD4 T cells can be activated to elicit antibody pro-
duction without signi¢cant cytokine secretion.
2. Materials and methods
2.1. Animals
OVA323^339-speci¢c TCR transgenic mice (OVA23-3) with the
BALB/c genetic background were produced as described previously
[6] and maintained by backcrossing to BALB/c mice in our animal
facility. BALB/c mice (female, 6 weeks old) were purchased from
Japan CLEA Inc. (Tokyo, Japan).
2.2. Synthetic peptides
OVA323^339 was prepared by solid-phase peptide synthesis using
an automated peptide synthesizer model 430A (PE Applied Biosys-
tems, Foster City, CA, USA), and puri¢ed by reverse-phase HPLC. A
series of single amino acid-substituted analogs of OVA323^339 (Table
1) was purchased from Chiron Mimotopes Pty Ltd (Clayton, Vic.,
Australia).
2.3. Preparation of naive CD4 T cells, resting B cells, and antigen-
presenting cells
Splenic CD4 T cells were isolated from OVA23-3 mice by positive
selection using anti-CD4-FITC monoclonal antibodies (GK1.5, Phar-
Mingen, San Diego, CA, USA) and a MACS anti-FITC multisort kit
(Miltenyi Biotech, Bergisch Gladbach, Germany). To obtain naive
CD4 T cells, the CD4 T cells were further separated into cells
expressing high levels of CD62L (a naive T cell marker) by positive
selection using anti-CD62L microbeads (Miltenyi Biotech). Splenic B
cells were puri¢ed from BALB/c mice by positive selection using anti-
B220 microbeads (Miltenyi Biotech). The B cells were further fractio-
nated into small resting B cells (60/70% interface) on discontinuous
Percoll gradients (50/60/70%). T cell-depleted antigen-presenting cells
(APCs) were prepared from spleen cells of BALB/c mice by negative
selection using anti-Thy1.2 microbeads (Miltenyi Biotech), and were
treated with 50 Wg/ml mitomycin C (Sigma, St. Louis, MO, USA).
Isolated naive CD4 T cells, resting B cells, and APCs were routinely
s 96% CD4CD62Lhigh, s 98% B220, and 6 5% Thy1.2, respec-
tively.
2.4. T cell proliferation assay
Naive CD4 T cells (1U105/well) in a total volume of 200 Wl were
stimulated with each peptide at 5 WM in the presence of APCs
(3U105/well) in 96-well £at bottom plates (Falcon; Becton Dickinson
Labware, Franklin Lakes, NJ, USA). The cells were cultured for 96 h.
Proliferation was assessed by measuring the incorporation of
[3H]thymidine (1 WCi/well) added for the ¢nal 24 h of culture.
2.5. Cytokine secretion
Naive CD4 T cells (1U105/well) in a total volume of 200 Wl were
stimulated with each peptide at 5 WM in the presence of APCs
Table 1
List of peptides used in this study
Peptide designation Amino acid sequencea
323 330 339
OVA323^339b Ile Ser Gln Ala Val His Ala Ala His Ala Glu Ile Asn Glu Ala Gly Arg
A326S ^ ^ ^ Ser ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^
A326L ^ ^ ^ Leu ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^
A326Q ^ ^ ^ Gln ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^
A326Y ^ ^ ^ Tyr ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^
A326E ^ ^ ^ Glu ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^
A326R ^ ^ ^ Arg ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^
H328K ^ ^ ^ ^ ^ Lys ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^
H328Y ^ ^ ^ ^ ^ Tyr ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^
H328Q ^ ^ ^ ^ ^ Gln ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^
H328L ^ ^ ^ ^ ^ Leu ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^
H328E ^ ^ ^ ^ ^ Glu ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^
H328S ^ ^ ^ ^ ^ Ser ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^
A329S ^ ^ ^ ^ ^ ^ Ser ^ ^ ^ ^ ^ ^ ^ ^ ^ ^
A329L ^ ^ ^ ^ ^ ^ Leu ^ ^ ^ ^ ^ ^ ^ ^ ^ ^
A329Q ^ ^ ^ ^ ^ ^ Gln ^ ^ ^ ^ ^ ^ ^ ^ ^ ^
A329Y ^ ^ ^ ^ ^ ^ Tyr ^ ^ ^ ^ ^ ^ ^ ^ ^ ^
A329E ^ ^ ^ ^ ^ ^ Glu ^ ^ ^ ^ ^ ^ ^ ^ ^ ^
A329R ^ ^ ^ ^ ^ ^ Arg ^ ^ ^ ^ ^ ^ ^ ^ ^ ^
A330S ^ ^ ^ ^ ^ ^ ^ Ser ^ ^ ^ ^ ^ ^ ^ ^ ^
A330L ^ ^ ^ ^ ^ ^ ^ Leu ^ ^ ^ ^ ^ ^ ^ ^ ^
A330Q ^ ^ ^ ^ ^ ^ ^ Gln ^ ^ ^ ^ ^ ^ ^ ^ ^
A330Y ^ ^ ^ ^ ^ ^ ^ Tyr ^ ^ ^ ^ ^ ^ ^ ^ ^
A330E ^ ^ ^ ^ ^ ^ ^ Glu ^ ^ ^ ^ ^ ^ ^ ^ ^
A330R ^ ^ ^ ^ ^ ^ ^ Arg ^ ^ ^ ^ ^ ^ ^ ^ ^
H331K ^ ^ ^ ^ ^ ^ ^ ^ Lys ^ ^ ^ ^ ^ ^ ^ ^
H331Q ^ ^ ^ ^ ^ ^ ^ ^ Gln ^ ^ ^ ^ ^ ^ ^ ^
H331L ^ ^ ^ ^ ^ ^ ^ ^ Leu ^ ^ ^ ^ ^ ^ ^ ^
H331E ^ ^ ^ ^ ^ ^ ^ ^ Glu ^ ^ ^ ^ ^ ^ ^ ^
E333D ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ Asp ^ ^ ^ ^ ^ ^
E333Q ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ Gln ^ ^ ^ ^ ^ ^
E333L ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ Leu ^ ^ ^ ^ ^ ^
E333A ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ Ala ^ ^ ^ ^ ^ ^
E333Y ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ Tyr ^ ^ ^ ^ ^ ^
E333R ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ Arg ^ ^ ^ ^ ^ ^
I334L ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ Leu ^ ^ ^ ^ ^
I334Q ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ Gln ^ ^ ^ ^ ^
I334S ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ Ser ^ ^ ^ ^ ^
I334Y ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ Tyr ^ ^ ^ ^ ^
I334D ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ Asp ^ ^ ^ ^ ^
I334R ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ Arg ^ ^ ^ ^ ^
aDashes indicate identity with the OVA323^339 sequence.
bA peptide corresponding to region 323^339 of OVA.
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(3U105/well) in 96-well £at bottom plates. The culture supernatants
were recovered after 24 h for measurement of IL-2 or after 72 h for
IL-4 and IFN-Q. The cytokine content was determined by means of a
two-site enzyme-linked immunosorbent assay (ELISA) as described
previously [7]. The pairs of primary and biotinylated secondary cap-
ture antibodies used were as follows: JES6-1A12 (PharMingen) and
JES6-5H4 (PharMingen) for IL-2, BVD4-1D11 (PharMingen) and
BVD6-24G2 (PharMingen) for IL-4, and R4-6A2 and XMG1.2 [7]
for IFN-Q.
2.6. Antibody production
Naive CD4 T cells (1U105/well) and resting B cells (1U105/well)
in a total volume of 200 Wl were co-cultured with each peptide at 5 WM
in the presence of APCs (3U105/well) in 96-well £at bottom plates.
The culture supernatants were recovered after 7 days. The levels of
total IgM and IgG were measured by two-site ELISA as described
previously [8] except that goat anti-IgM antibody (Cappel-Organon
Teknika, Durham, NC, USA) and alkaline phosphatase-conjugated
goat anti-IgM antibody (Zymed, South San Francisco, CA, USA)
were used as the primary and secondary capture antibodies, respec-
tively.
3. Results
A study examining the crystal structure of the OVA323^
339/I-Ad molecule complex has revealed that the side groups
of residues 327Val and 332Ala are critical for I-Ad binding and
that those of other residues in the region 325^334 seem to
interact with TCR [9]. On the basis of this information, we
prepared analog peptides with a single amino acid substitution
at one of seven putative TCR contact residues, 326Ala, 328His,
329Ala, 330Ala, 331His, 333Glu, and 334Ile (Table 1).
We investigated the primary activation pro¢le of naive
CD4 T cells upon stimulation with each peptide by measur-
ing proliferation (Fig. 1), cytokine secretion (Fig. 2), and the
ability to provide help for antibody secretion by B cells (Fig.
3). All assays were performed at a single peptide concentra-
tion to exclude the dose e¡ect. A relatively high concentra-
tion, 5 WM, was selected, since our preliminary experiments
showed that some of the peptides that elicited a T cell re-
sponse at 5 WM induced no detectable response at lower con-
centrations. At this peptide concentration (5 WM), OVA323^
339 induced strong proliferation, and e⁄cient secretion of IL-
2 and IFN-Q, which is a typical Th1-type response. The wild-
type peptide did not activate T cells to provide help to resting
B cells to secrete antibodies.
No analog peptide tested with a substitution at residue
328His or 331His induced proliferation, cytokine secretion, or
antibody secretion. Likewise, analogs with a substitution at
residue 334Ile elicited no T cell response, except for I334L,
having a highly conservative substitution, which induced these
responses to the same extent as OVA323^339. These results
show that residues 328His, 331His, and 334Ile are absolutely
required for recognition by the TCR in our system.
In contrast, some analogs with a substitution at residue
326Ala, 329Ala, 330Ala, or 333Glu induced T cell responses qual-
itatively di¡erent from those induced by OVA323^339.
A326Q induced strong proliferation and IL-4 secretion with-
out production of IL-2 and IFN-Q, which is a typical Th2-type
response. A326R also elicited the Th2-type response, but more
weakly than A326Q. A326R activated T cells to provide help
to resting B cells to secrete large amounts of IgM and IgG,
whereas A326Q induced lower levels of IgM and IgG secre-
tion. A326S having a more conservative substitution induced
the same response as that induced by OVA323^339. A326Y
elicited very weak proliferation and a weak antibody response
with no apparent cytokine production. A326L and A326E
elicited no T cell response.
Among the analogs with a substitution at residue 329Ala,
only A329S and A329Q elicited weak T cell responses. A329S
induced a cytokine response similar to the typical Th2-type
response elicited by A326R except for a low level of IL-2
secretion. This peptide also elicited a very weak antibody re-
sponse, as compared with that elicited by A326R. A329Q
elicited weak proliferation and antibody secretion without cy-
tokine secretion.
With regard to the analogs with a substitution at residue
330Ala, A330Q elicited responses quite similar to those elicited
by A329S. A330S and A330L having a conservative substitu-
tion induced the same responses as those induced by
OVA323^339, whereas A330Y, A330E, and A330R elicited
no T cell response.
Finally, the analogs with a substitution at residue 333Glu
induced various types of responses. E333A induced prolifer-
ation and cytokine responses very similar to those observed in
the case of A326R but a weaker IgG response. The response
induced by E333D was quite distinct in that there was no
detectable cytokine secretion and only weak proliferation,
but an unexpectedly high level of antibody secretion. E333L
elicited strong proliferation and a weak antibody response,
with low-level secretion of IL-2 and IFN-Q, and modest IL-4
secretion. E333Q elicited the same responses as those observed
in the case of OVA323^339. E333Y and E333R elicited no
T cell response.
Fig. 1. Proliferation of naive CD4 T cells in response to single
amino acid-substituted analogs of OVA323^339. Naive CD4 T
cells (1U105/well) were stimulated with each peptide at 5 WM in the
presence of APC (3U105/well) for 96 h, and [3H]thymidine uptake
during the last 24 h was measured. The results shown are represen-
tative of three independent experiments. The value (cpm þ S.D.) of
the background indicated as None was 267 þ 4.
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4. Discussion
In the present study, we assessed the primary response of
naive CD4 T cells upon stimulation with analog peptides
having a single amino acid substitution. The primary response
of naive CD4 T cells elicited by altered TCR ligands (Figs.
1^3) can be classi¢ed into at least four types in addition to a
null response (Table 2): (A) a Th1-type cytokine response
with strong proliferation and no induction of antibody pro-
duction, (B) a Th2-type cytokine response with strong prolif-
eration and ine⁄cient induction of antibody production, (C) a
weak Th2-type cytokine response with weak proliferation and
e⁄cient induction of antibody production, and (D) no detect-
able cytokine response but with weak proliferation and e⁄-
cient induction of antibody production. These results clearly
show that naive CD4 T cells can display a Th1- or Th2-type
cytokine secretion pro¢le immediately after primary stimula-
tion with altered peptide ligands. We also demonstrate that
naive CD4 T cells can be activated to elicit antibody pro-
duction, even if they do not secrete detectable levels of cyto-
kines. Our study has revealed for the ¢rst time the distinct
activation pro¢les of naive CD4 T cells displayed in their
primary response upon stimulation with altered TCR ligands.
Previous studies demonstrating di¡erentiation of naive
CD4 T cells into Th1/Th2 subsets in vitro did not show
such distinct cytokine responses upon primary stimulation
of freshly isolated naive T cells [10,11]. In those studies, the
cytokine levels following secondary stimulation were about
200^500-fold higher than those observed after primary stim-
ulation in the present study. Very low levels of cytokine se-
cretion in the primary response such as we observed may have
been ignored or undetectable in those previous studies. Other-
wise, the levels of cytokine secretion in the primary response
may vary depending on the strain of TCR-transgenic mice
and/or the individual mice used in each experimental system.
Nevertheless, it is obvious from our results that low levels but
distinct Th1- or Th2-type cytokine secretion pro¢les can be
induced in the primary response of naive CD4 T cells, and
these are considered to drive naive CD4 T cells to di¡er-
entiate into e¡ector Th1/Th2 cells in an autocrine manner.
Our analysis of T cell responses to analog peptides have
revealed that the residues 328His, 331His, and 334Ile of
OVA323^339 are essential for the interaction with transgenic
TCR in OVA23-3 mice. It was previously shown that 331His is
commonly required for recognition by the TCR of several
OVA323^339-speci¢c T cells [12]. Furthermore, analysis of
the crystal structure of the OVA323^339/I-Ad complex [9]
has shown that 328His and 331His are located in positions
adequate for TCR binding. On the other hand, substitution
at residue 326Ala, 329Ala, 330Ala, or 333Glu led to several
changes in the responses of naive CD4 T cells, although
substitution at residue 329Ala or 330Ala was less e¡ective in
Fig. 2. Cytokine secretion by naive CD4 T cells upon primary stimulation with analog peptides. Naive CD4 T cells (1U105/well) were stimu-
lated with each peptide at 5 WM in the presence of APC (3U105/well). The culture supernatants were recovered after 24 h or 72 h for measure-
ment of IL-2 or IL-4 and IFN-Q, respectively. The cytokine levels were determined by ELISA. The results shown are representative of three in-
dependent experiments. The detection limit was 313 pg/ml for IL-2, 93.7 pg/ml for IFN-Q, and 1.9 pg/ml for IL-4.
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causing these changes. Allen et al. [13] have found a hierarchy
in the importance of individual amino acid residues contacting
TCR in an antigenic peptide. The primary contact residues are
indispensable for binding to TCR, and the secondary contact
sites are de¢ned as TCR contact sites which are assumed to
play a lesser role in the interaction and are permissive for
substitutions. When we adapt our ¢ndings to this hypothetical
hierarchy, 328His, 331His, and 334Ile seem to be the primary
contact residues, and 326Ala, 329Ala, 330Ala, and 333Glu seem
to be the secondary contact residues in our system. When
some amino acid substitution was introduced at these secon-
dary TCR contact residues, T cell responses could be modi¢ed
in terms of the cytokine response pattern and/or antibody
production helping activity.
Changes in the T cell response patterns were highly depend-
ent on the side groups of the amino acid residues substituted
for the wild-type ones. We focused on substitutions at residues
326Ala, 329Ala, 330Ala and 333Glu where some substitutions
caused a qualitative change in the T cell response. All analog
peptides with a substitution of a charged residue (Glu or Arg)
for Ala at residue 326, 329 or 330 completely lost the capa-
bility to activate T cells, except for A326R which elicited a
type C response as described in Table 2. Similarly, four out of
six analogs with a substitution of an amino acid having a
hydrophobic side chain with a large molecular mass (Leu or
Tyr) for an Ala residue induced no T cell response. Therefore,
substitution of an amino acid residue having a large molecular
mass or a charged side chain for Ala seems to have a tendency
to abolish the capability to elicit a T cell response. In contrast,
all peptides with a substitution of a non-charged polar amino
acid (Ser or Gln) for Ala retained the capability to elicit some
T cell response. Four out of six analogs with such a substitu-
Fig. 3. Antibody production by B cells co-cultured with naive CD4 T cells upon stimulation with analog peptides. Naive CD4 T cells
(1U105/well) and resting B cells (1U105/well) were stimulated with each peptide at 5 WM in the presence of APC (3U105/well). The culture
supernatants were recovered after 7 days. The levels of total IgM and IgG were measured by ELISA. The results shown are representative of
three independent experiments. The detection limit was 39 ng/ml for IgM and 15 ng/ml for IgG.
Table 2





Proliferation Cytokine secretion Helper activity for
antibody secretion
IL-2 IFN-Q IL-4
A OVA323^339 +++b +++ +++ 3 3
B A326Q +++ 3 3 +++ +
C A326R ++ 3 3 + +++
D E333D + 3 3 3 ++
aOther peptides which elicited each type of response are as follows: (A) A326S, A330S, A330L, E333Q, and I334L; (B) E333L; (C) A329S,
A330Q, and E333A; and (D) A326Y and A329Q. The rest of the peptides tested elicited no response.
b+++, ++, + or 3, means s 70%, 40^70%, 10^40%, or 6 10%, respectively, of the maximal response induced by the peptide with the highest
e⁄ciency in inducing each response.
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tion induced a qualitative change in the T cell response
(A326Q, type B; A329S and A330Q, type C; A329Q, type
D). As for analog peptides with a substitution at residue
333Glu, half of them caused a qualitative change in the T
cell response (E333L, type B; E333A, type C; E333D, type
D). Taken together, it appears that modi¢cation at the posi-
tion of a charged residue or substitution of a non-charged
polar amino acid residue for a small non-polar amino acid
residue in an antigenic peptide would be a good approach to
modify T cell responses elicited by the peptide qualitatively.
Since we did not test all possible substitutions at the relevant
residues, a general rule regarding the relationship between
amino acid substitution and alteration of T cell responses
could not be established. However, when the 3D structure
of the complex of OVA323^339/I-Ad and the TCR expressed
in our transgenic mice has been revealed, the present ¢ndings
will be useful to elucidate the structural basis for the modi¢ed
T cell response induced by altered peptide ligands.
An unexpected ¢nding in this study was that an antibody
response can be elicited even if the T cells secrete no detect-
able cytokines. To produce antibodies in response to T cell-
dependent antigens, B cells require two signals derived from
activated T cells [14,15]. The ¢rst one is mediated by cyto-
kines, especially those secreted from Th2 cells, such as IL-4.
The second signal is mediated by interaction between cell sur-
face molecules on T cells and B cells. Molecules expressed on
activated T cells, such as CD40 ligand, OX40 and Fas ligand,
are important for regulation of T cell-dependent activation of
B cells [16,17]. Our results show that the extent of IL-4 pro-
duction by T cells stimulated with the analog peptides was not
simply correlated with their antibody production-inducing ac-
tivity, although it is still possible that an undetectable level of
the cytokine was secreted upon stimulation with the antibody-
eliciting peptides. Thus it is likely that the patterns of expres-
sion of each of the surface molecules rather than the Th2-type
cytokine response of T cells may be modulated by analog
peptides through modi¢cation of the TCR/antigen/MHC in-
teraction, resulting in di¡erent antibody responses of B cells.
Further analysis of the levels of expression of these molecules
will help to clarify the precise mechanism which controls the
di¡erent antibody responses of B cells induced by altered pep-
tide ligands. In our present experiments, we investigated the
antibody response of polyclonal B cells interacting with T cells
speci¢c for OVA323^339, as a primary step in the study. We
should further examine the antigen-speci¢c interactions be-
tween T cells and B cells with the same antigen speci¢city.
We expect that studies using analog peptides eliciting each
of the four types of responses illustrated in Table 2 will
shed light on the precise mechanism underlying T cell helper
activity for the antibody response.
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